Fluvalinate
Fluvalinate is an orally active acaricide classified as a sodium channel inhibitor. Fluvalinate delays sodium channel closure, prolongs cell membrane depolarization, inhibits the excitability of honeybee brain neurons, and exerts a central nervous system inhibitory effect. Fluvalinate negatively affects the learning ability, memory ability, sucrose responsiveness, and survival of honeybees. Fluvalinate potentiates pentobarbital-induced hypnosis, reduces spontaneous activity in mice, and decreases the total white blood cell count and absolute lymphocyte count in mice. Fluvalinate induces acute toxic symptoms in rats, acts as a cholinergic stimulant, and induces the production of hepatic enzymes in rats. Fluvalinate causes the death of Varroa jacobsoni sensitive to τ-Fluvalinate (HY-B2021). Fluvalinate can be used in studies related to mite pest control.
For research use only. We do not sell to patients.
- CAS No.: 69409-94-5
- Formula: C26H22ClF3N2O3
- Molecular Weight:502.91
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Fluvalinate (0.25-2.5% w/v) produces negative inotropic and negative chronotropic effects on isolated frog hearts, and complete myocardial block occurs at 2.5% w/v[1].
Fluvalinate (0.3-3.0 μg per vial; 24 h) has an LC90 of 2.4 μg per vial (95% CI 1.4-8.2 μg), and induces a mortality rate of 80.3% in fluvalinate-sensitive Varroa mites from southern Texas following 24 h of exposure in a glass vial residual bioassay[4].
Fluvalinate (2.4 μg per tube; 24 h) results in a 73.3% mortality rate of Varroa jacobsoni from other apiaries in Texas (with no significant difference from susceptible mites), a 23.7% mortality rate of mites from Florida, and a 65.1% mortality rate of mites from California; it also induces consistent mortality rates of Varroa mites in 3 hives within the same fluvalinate-susceptible apiary in Texas[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Fluvalinate (15 mg/kg; i.p.; once daily; for 15 consecutive days) induces significant body weight loss, hematological changes, and liver-kidney-spleen toxicity in male Swiss albino mice[1].
Fluvalinate (0.125-1.25 μg; oral, transdermal; single administration) negatively affects the learning ability, memory ability, sucrose responsiveness, and survival of honey bees in a dose-dependent manner[2].
Fluvalinate (62.5-500 mg/kg; oral administration; single dose) has an acute oral LD50 value of 293 mg/kg in male Wistar rats and 280 mg/kg in female Wistar rats, and induces dose-dependent toxic signs[3].
Fluvalinate (17.5-70 mg/kg/day; oral administration; once daily for 15 consecutive days) causes a significant dose-dependent reduction in pentobarbital-induced sleep time in female Wistar rats[3].
Fluvalinate (17.5-70 mg/kg/day; oral administration; once daily for consecutive 21 days) induces mild transient cholinergic symptoms in female Wistar rats, significantly increases AST and BUN levels as well as the relative weight of the adrenal glands; at doses of 35 and 70 mg/kg/day, it significantly reduces estrogen levels; the dose of 70 mg/kg/day also increases the relative weight of the liver and decreases the relative weight of the spleen[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss albino (male, 20-32 g)[1]
-
Dosage:7.5 mg/kg; 15 mg/kg; 30 mg/kg; 60 mg/kg; 100 mg/kg
-
Administration:i.p.; single dose; once daily for 3 consecutive days
-
Result:Prolonged pentobarbitone sleeping time dose-dependently at single doses of 7.5-60 mg/kg, with durations ranging from 72.66 to 292.20 min.
Shortened pentobarbitone sleeping time to 44.50 min after three consecutive daily 15 mg/kg pretreatments.
Suppressed spontaneous locomotor activity to 9.04%-22.03% of control within 4 h post single 15 mg/kg dose, without altering forced locomotion.
Triggered transient CNS stimulation followed by severe CNS depression and 42.86% mortality at single 100 mg/kg dose.
-
Animal Model:Swiss albino (male, 20-32 g)[1]
-
Dosage:15 mg/kg
-
Administration:i.p.; once daily; 15 days
-
Result:Lowered mean live weight to 26.62 g vs control 32.13 g.
Cut total leukocyte count.
Dropped absolute lymphocyte count.
Decreased relative spleen weight.
Triggered renal glomerular hypertrophy, narrowed Bowman’s space, mild renal degeneration and cortical tubular hyalinization.
Produced hepatic cloudy swelling and fatty degeneration.
Destroyed normal splenic pulp demarcation, disrupted lymphoid nodule edges and accumulated white pulp lymphocytes.
Exerted no toxic lesions in lung, heart and testis tissues.
-
Animal Model:Apis mellifera Buckfast strain (older forager/guard individuals)[2]
-
Dosage:0.125 μg; 1.25 μg
-
Administration:oral; single dose; dermal; single dose
-
Result:Impaired odour-reward learning more by oral exposure than dermal exposure.
Reduced learning scores most at high oral dose versus dermal control.
Minimized memory recall at high oral dose; low dermal dose barely affected memory.
Suppressed sucrose response sharply at high oral dose (Colony1:3.0 vs 6.4; Colony2:2.1 vs 5.1).
Triggered drooping proboscis in ~30% bees pre-sucrose stimulation under high oral dose.
Boosted mortality dose-dependently; oral exposure more lethal, high oral dose had peak 24 h colony mortality.
-
Animal Model:Wistar rats (male and female, adult, 160-180 g)[3]
-
Dosage:62.5 mg/kg; 125 mg/kg; 250 mg/kg; 500 mg/kg
-
Administration:p.o.; single dose
-
Result:Observed no gross toxic effects at 62.5 mg/kg.
Induced hyperactivity, incoordination, ataxia, clonic convulsions, profuse sweating, salivation, piloerection, hypothermia, dyspnoea, and death at 125-500 mg/kg.
Caused marked hypothermia within 1 hour of administration, persisting up to 24 hours in surviving animals with peak effect at 12 hours.
Calculated acute oral LD50 values of 293 mg/kg in male rats and 280 mg/kg in female rats.
-
Animal Model:Wistar rats (female, adult, 160-180 g)[3]
-
Dosage:17.5 mg/kg/day; 35.0 mg/kg/day; 70.0 mg/kg/day
-
Administration:p.o.; daily; 21 days
-
Result:Showed no abnormal behaviours at 17.5 mg/kg/day.
Triggered reversible sweating and salivation on days 3-7 at 35 and 70 mg/kg/day.
Altered none of tested blood routine indexes across all doses.
Raised AST and BUN, slightly lifted glucose, lowered E2, enlarged adrenal glands and shrank spleen at 35 and 70 mg/kg/day.
Boosted relative liver weight only at 70 mg/kg/day.
Left ALT, cholesterol, protein, albumin, P4 and relative kidney weight unchanged in all groups.
-
Animal Model:Wistar rats (female, adult, 160-180 g)[3]
-
Dosage:17.5 mg/kg/day; 35.0 mg/kg/day; 70.0 mg/kg/day
-
Administration:p.o.; daily; 15 days
-
Result:Cut pentobarbital sleeping time dose-dependently: 57.40, 47.00, 25.33 min at 17.5, 35, 70 mg/kg/day vs control 84.06 min.
Raised relative liver weight slightly without altering total liver protein at 17.5 mg/kg/day.
Elevated total liver protein at 35 mg/kg/day.
Boosted both relative liver weight and total liver protein at 70 mg/kg/day.
Chemical Information
-
CAS No. 69409-94-5
-
Molecular Weight 502.91
-
Formula C26H22ClF3N2O3
-
SMILES
CC(C(NC1=CC=C(C=C1Cl)C(F)(F)F)C(OC(C2=CC=CC(OC3=CC=CC=C3)=C2)C#N)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fluvalinate Related Classifications
HY-123320 Related Classifications
Powered by Bioz